l-Carnitine and heart disease.

Area of Science:

• Cardiology and Metabolic Disorders
• Mitochondrial Function and Energy Metabolism
• Pharmacology and Therapeutics

Background:

• Cardiovascular disease (CVD) is a leading global cause of mortality, with significant healthcare costs.
• Current CVD treatments like beta-blockers and ACE inhibitors have adverse effects, necessitating alternative strategies.
• Carnitine depletion, linked to CVD, highlights the importance of carnitine in cardiac health.

Purpose of the Study:

• To explore l-carnitine as a cardioprotective agent and alternative therapeutic strategy for cardiovascular diseases.
• To elucidate the mechanisms by which l-carnitine influences cardiac energy metabolism and cellular homeostasis.
• To review the efficacy of l-carnitine in managing various cardiovascular pathologies and associated metabolic conditions.

Main Methods:

• Review of existing literature on l-carnitine's role in cardiovascular health.
• Analysis of l-carnitine's biochemical pathways, including mitochondrial beta-oxidation and fatty acid transport.
• Examination of clinical evidence supporting l-carnitine's benefits in different patient populations and conditions.

Main Results:

• l-Carnitine enhances mitochondrial beta-oxidation, balancing cardiac energy metabolism and providing cardioprotection.
• It reduces oxidative stress, inflammation, and myocyte necrosis, while regulating cellular homeostasis.
• Exogenous l-carnitine administration demonstrates efficacy against ventricular dysfunction, ischemia-reperfusion injury, and arrhythmias.

Conclusions:

• l-Carnitine is a safe and effective therapeutic agent for various cardiovascular conditions, including cardiomyopathy.
• It mitigates cardiovascular risk factors such as hypertension, hyperlipidemia, and diabetes.
• l-Carnitine supplementation represents a valuable strategy for preventing and treating cardiovascular diseases across all age groups.